La EMA TRAE A EUROPA UN 5.° TRATAMIENTO PARA PRIMERA LINEA SMALL CELL LUNG CÁNCER ( SERPLULIMAB ) . POSITIVO : L@s PACIENTES y ONCÓLOGOS TIENEN MÁS OPCIONES PARA ELEGIR ... NEGATIVO : LOS INGRESOS POR VENTAS HAY MÁS FARMACÉUTICAS A REPARTIRSELOS .

SERPLULIMAB DE HENLIUS YA ESTA APROBADA PARA SMALL-CELL LUNG CÁNCER DE PRIMERA LÍNEA EN CHINA , INDONESIA , INDIA Y EUROPA ( 30 PAISES ) .

... EN ESTADOS UNIDOS SU APROBACIÓN SE PRODUCIRÁ EN BREVE . LA EMA EN ESTA OCASIÓN SE HA ADELANTÓ A LA USFDA EN LA APROBACIÓN DE UN TRATAMIENTO .

Hasta Hace Pocos Días Solo Existían 4 Tratamientos Para Primera Línea SMALL CELL LUNG CÁNCER :

*.- CARBOPLATINO + ETOPÓSIDO .

*.- CISPLATIN + ETOPÓSIDO .

*.- ATEZOLIZUMAB .

*.- DURVALUMAB .

Tras la Aprobación Por Parte de la EMA del SERPLULIMAB ... Serán Ya Cinco los Tratamientos a Elegir Por Pacientes y Oncolog@s  ... Y Lógicamente con Cada Nueva Aprobación ... las Farmacéuticas Serán Más a Repartirse las Ventas .

• SERPLULIMAB is the world's first anti-PD-1 Monoclonal Antibody (mAb) Approved for FIRST-LINE Treatment of ES-SCLC .

• SERPLULIMAB is the FIRST and only anti-PD-1 mAb Approved in the European Union (EU) for the Treatment of ES-SCLC .

• SERPLULIMAB Has Now Been Approved in China, Europe, and several Southeast Asian Countries, Benefiting Over 90,000 Patients .

Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG ( SERPLULIMAB, Marketed as HETRONIFLY ^® in EUROPE ), has been officially approved by the European Commission (EC) for use in Combination with CARBOPLATIN and ETOPÓSIDE as a FIRST-LINE Treatment of adult Patients with ES-SCLC .

 This APPROVAL establishes SERPLULIMAB as the FIRST and Only anti-PD-1 mAb Approved in the EU for the Treatment of ES-SCLC. 

SERPLULIMAB is the world's FIRST Anti-PD-1 mAb Approved For FIRST-LINE Treatment of ES-SCLC. Underpinned by Clinical Needs, Henlius has carried out a differentiated and multi-dimensional layout of SERPLULIMAB in the fields of Lung Cáncer and Gastrointestinal Cáncer . To date, more than 4,800 subjects have been enrolled Worldwide for clinical trials of SERPLULIMAB . In 2023, Henlius entered into a collaboration with INTAS Pharmaceuticals, granting INTAS Exclusive Rights to Develop and Commercialise SERPLULIMAB in Over 50 Countries Across Europe and India . 

This Latest APPROVAL covers all 27 EU Member States as well as the European Economic Area Countries, including Norway, Iceland, and Liechtenstein. Commercialisation in Europe will be led by INTAS' Subsidiary, Accord Healthcare Ltd ("Accord") .

...